Table 2 Cross-sectional demographics and clinical characteristics of the studied population based on the Ptau/Aβ1-42 ratio score
From: Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
Ptau/Aβ + (n=36) | Ptau/Aβ – (n=64) | p | |
|---|---|---|---|
Ptau/Abeta42 ratio | 0.04 (0.012) | 0.01 (0.003) | |
Aβ level (mean, SD) | 685.2 (163.7) | 1494.2 (401.9) | |
Sex (male/female) | 26/10 | 36/28 | 0.166 |
BMI (mean, SD) | 26.2 (3.8) | 25.3 (3.7) | 0.338 |
Age (years, mean, SD | 73.8 (4.9) | 72.0 (4.4) | 0.039 |
APOE ε4 carrier (n, %) | 18 (50%) | 14 (22.6%) | 0.001 |
MMSE (mean, SD) | 28.5 (1.5) | 28.8 (1.4) | 0.314 |
CDR (mean, SD) | 0 (0) | 0 (0) | |
GFAP pg/mL (mean, SD) | 211.8 ± 97.6 | 138.8 ± 49.9 | <0.001 |
YKL-40 pg/mL (mean, SD) | N=38 87038.7 ± 74252.3 | N=145 60583.7 ± 54067.1 | 0.012 |
MCP-1 pg/mL (mean, SD) | N=34 92.6 ± 18.4 | N=64 96.4 ± 30.7 | 0.602 |
Eotaxin-1 pg/mL (mean, SD) | N=34 193.6 ± 62.9 | N=64 202.5 ± 86.7 | 0.630 |